ReNeuron Announces Board Changes

ReNeuron Group plc (AIM: RENE), a UK-based Stem Cell and Exosomes technologies company, has announced that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.

Following these changes, the ReNeuron Board now comprises of five directors as follows: Iain Ross (Executive Chairman); Catherine Isted (CFO and Executive Director) and three independent Non-Executive Directors – Dr Michael Owen, Barbara Staehelin and Martin Walton, ReNeuron said in its press release.

Iain Ross, Chairman of ReNeuron, commented: “On behalf of the Board and Management I would like to thank Tim Corn for his service to the Company over the last nine years and to recognise his contribution as a director and former Chairman of ReNeuron. Also, I want to thank Mark Evans for the invaluable support he has provided over the last two years as a director and representative of Obotritia, a significant shareholder in ReNeuron.

“I would like to welcome Martin Walton to the ReNeuron Board as we look to re-focus the business. Martin, a former investment banker, has completed more than 25 transactions in the last 12 years as a principal or advisor which has included start-up and spin-out investments, pre-IPO and IPO funding; M&A and over $1bn in investment and co-investment capital. He is the co-founder of LSE-listed Arix Bioscience plc (LSE: ARIX) and his current roles include serving as CEO of Excalibur Medicines Ltd and a Board Member of the Liverpool Life Sciences Accelerator Partnership. He brings a wealth of relevant experience in the life sciences sector.”